Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rolofyline · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | rolofyline 2.5 mg IV QD |
| 2 | EXPERIMENTAL | rolofyline 15 mg IV QD |
| 3 | EXPERIMENTAL | rolofyline 30 mg IV QD |
| 4 | EXPERIMENTAL | rolofyline 60 mg IV QD |
| 5 | PLACEBO_COMPARATOR | placebo for rolofyline IV QD |
| Name | Type | Description |
|---|---|---|
| rolofyline | DRUG | rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days |
| Comparator Placebo (unspecified) | DRUG | Matching placebo for rolofyline IV QD; 3 days |
Inclusion Criteria: * Be able to provide written informed consent, * Be a male or female at least 18 years of age, * Be hospitalized for fluid overload requiring IV diuretic therapy * History of use of diuretic therapy for CHF (including this admission), * Be admitted to the hospital within 36 hour...
Rolofyline is an investigational small molecule being studied for congestive heart failure, a condition in which the heart cannot pump blood effectively. It is being developed as a potential treatment to address fluid retention and related symptoms in patients with this condition.
Rolofyline is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with congestive heart failure.
Rolofyline is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness in treating congestive heart failure.
Rolofyline has been studied in one completed Phase 2 clinical trial registered as NCT00652782, titled 'Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients.' The trial enrolled 160 participants with congestive heart failure and renal impairment, was randomized, double-blind, and placebo-controlled.
Yes, rolofyline is also known as MK7418. The clinical trial NCT00652782 refers to the drug as MK7418, which is the same investigational compound being developed by Merck & Company, Inc. for congestive heart failure.
Rolofyline is a small molecule designed to target mechanisms involved in fluid regulation in the body. In the context of congestive heart failure, it is being studied for its effects on diuresis, or urine production, and renal function, which are important for managing fluid overload in patients.